Professor Michael Kleiner Shochat

Professor Michael Kleiner Shochat

Hillel Yaffe Medical Center, Hadera (Israel)

Engineer in electronics and medical devices. Since 2012 Professor in Cardiology and Director Heart Failure Unit in Hillel Yaffe hospital in Israel.

Presentations

Early Intervention with Impedance-guided Heart Failure Management Improves Long-term Outcome: Insights From the IMPEDANCE-HF Trial

Event: ESC Congress 2022

Topic: Nonpharmacological Treatment

Session: Contemporary management of acute heart failure

Access

Monitoring of the lung fluid status in hospitalized COVID-19 patients for predicts outcome. Results of the IMPEDANCE-Corona Trial

Event: ESC Congress 2022

Topic: Pathophysiology and Mechanisms

Session: Covid-19 and heart failure

Access

COVID-IMPEDANCE trial - Using lung impedance technique for monitoring COVID19 patients

Event: Heart Failure 2022

Topic: Clinical

Session: LBCS - Monitoring Devices

Access

Residual congestion on discharge for Heart Failure assessed by impedance technique predicts 30-day and one-year All-cause death. Results of IMPEDANCE-HF extended trial

Event: Heart Failure 2019

Topic: Prevention

Session: Acute Heart Failure

Access

Problem of 30-day readmission for Heart Failure could be improved. Results of IMPEDANCE-HF extended trial

Event: Heart Failure 2019

Topic: Nonpharmacological Treatment

Session: Acute Heart Failure

Access

Compeering of predictive accuracy for 30, 90 and 365-day Heart Failure readmission assessed by impedance technique and NT-proBNP. Results of IMPEDANCE-HF extended trial

Event: Heart Failure 2019

Topic: Diagnostic Methods

Session: Rapid Fire 3 - Acute heart failure

Access

Residual congestion on discharge for Heart Failure assessed by impedance technique predicts 30-day and one-year Heart Failure death. Results of IMPEDANCE-HF extended trial

Event: Heart Failure 2019

Topic: Epidemiology, Prognosis, Outcome

Session: Moderated Poster Session - Acute heart failure

Access

Thirty day and one-year risk stratification of Heart Failure Death According N-terminal pro-brain natriuretic peptide at discharge for Heart Failure hospitalization. Results of IMPEDANCE-HF extended t

Event: Heart Failure 2019

Topic: Biomarkers

Session: Acute Heart Failure

Access

Prediction of 30-day readmission for Heart Failure by N-terminal pro-brain natriuretic peptides. Results of IMPEDANCE-HF extended trial

Event: Heart Failure 2019

Topic: Biomarkers

Session: Acute Heart Failure

Access

Non-Invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: A Randomized Controlled Trial (IMPEDANCE-HF Trial)

Event: Heart Failure 2019

Topic: Nonpharmacological Treatment

Session: Clinical Forum - Sat.25 May 08:30 - Tues. 28 May at 12:30

Access

ESC 365 is supported by

Explore sponsored resources

Professor Michael Kleiner Shochat

Biography

Contributor content

Early Intervention with Impedance-guided Heart Failure Management Improves Long-term Outcome: Insights From the IMPEDANCE-HF Trial

Monitoring of the lung fluid status in hospitalized COVID-19 patients for predicts outcome. Results of the IMPEDANCE-Corona Trial

COVID-IMPEDANCE trial - Using lung impedance technique for monitoring COVID19 patients

Residual congestion on discharge for Heart Failure assessed by impedance technique predicts 30-day and one-year All-cause death. Results of IMPEDANCE-HF extended trial

Problem of 30-day readmission for Heart Failure could be improved. Results of IMPEDANCE-HF extended trial

Compeering of predictive accuracy for 30, 90 and 365-day Heart Failure readmission assessed by impedance technique and NT-proBNP. Results of IMPEDANCE-HF extended trial

Residual congestion on discharge for Heart Failure assessed by impedance technique predicts 30-day and one-year Heart Failure death. Results of IMPEDANCE-HF extended trial

Thirty day and one-year risk stratification of Heart Failure Death According N-terminal pro-brain natriuretic peptide at discharge for Heart Failure hospitalization. Results of IMPEDANCE-HF extended t

Prediction of 30-day readmission for Heart Failure by N-terminal pro-brain natriuretic peptides. Results of IMPEDANCE-HF extended trial

Non-Invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: A Randomized Controlled Trial (IMPEDANCE-HF Trial)

ESC 365 is supported by

Professor Michael Kleiner Shochat Follow

Biography

Contributor content

Early Intervention with Impedance-guided Heart Failure Management Improves Long-term Outcome: Insights From the IMPEDANCE-HF Trial

Monitoring of the lung fluid status in hospitalized COVID-19 patients for predicts outcome. Results of the IMPEDANCE-Corona Trial

COVID-IMPEDANCE trial - Using lung impedance technique for monitoring COVID19 patients

Residual congestion on discharge for Heart Failure assessed by impedance technique predicts 30-day and one-year All-cause death. Results of IMPEDANCE-HF extended trial

Problem of 30-day readmission for Heart Failure could be improved. Results of IMPEDANCE-HF extended trial

Compeering of predictive accuracy for 30, 90 and 365-day Heart Failure readmission assessed by impedance technique and NT-proBNP. Results of IMPEDANCE-HF extended trial

Residual congestion on discharge for Heart Failure assessed by impedance technique predicts 30-day and one-year Heart Failure death. Results of IMPEDANCE-HF extended trial

Thirty day and one-year risk stratification of Heart Failure Death According N-terminal pro-brain natriuretic peptide at discharge for Heart Failure hospitalization. Results of IMPEDANCE-HF extended t

Prediction of 30-day readmission for Heart Failure by N-terminal pro-brain natriuretic peptides. Results of IMPEDANCE-HF extended trial

Non-Invasive Lung IMPEDANCE-Guided Preemptive Treatment in Chronic Heart Failure Patients: A Randomized Controlled Trial (IMPEDANCE-HF Trial)

ESC 365 is supported by

Professor Michael Kleiner Shochat